About Synchroneuron
Synchroneuron is a company based in Newton (United States) founded in 2006 by William Kerns and Barry Fogel. Synchroneuron has raised $26 million across 2 funding rounds from investors including Morningside China. Synchroneuron operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Newton, United States
- Founders William Kerns, Barry Fogel
- SectorsHealthcare
- Website synchroneuron.com
- Social LinkedIn
- Total Equity Funding$26M (USD)
in 2 rounds
- Latest Funding Round$20M (USD), Series B
Jul 2014
- Investors
Funding Insights of Synchroneuron
Synchroneuron has successfully raised a total of $26M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in July 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26M
- Total Rounds 2
- Last Round Series B — $20M
- First Round $6M
(Feb 2012)
- Investors Count 1
All 2 funding rounds of Synchroneuron with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2014 | $20M | Series B | – | Morningside | – |
| Feb 2012 | $6M | Series A | – | Morningside | – |
1 investors in total: 1 institutional.
Investors in Synchroneuron
Synchroneuron has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Morningside China.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC and private equity investments are made in China-US companies. | – | morningside.com.cn | Shanghai, China |
Investor details for Synchroneuron
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Synchroneuron
2 people are tracked at Synchroneuron (2 in leadership).
| Name | Role | Group |
|---|---|---|
William Kerns | Co-Founder | Leadership |
Barry Fogel | Co-Founder & CEO | Leadership |
Complete people profiles for Synchroneuron
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Synchroneuron
3 dated milestones of Synchroneuron across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Synchroneuron is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series B, of $20.0M.
Competitors of Synchroneuron
Synchroneuron operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | – | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. | |
| cerecor.com | 2011 | Baltimore, United States | $45.2M | 20 | Therapeutics for immunological and neurological disorders are developed. | |
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| vandapharma.com | 2003 | – | $33.5M | 203 | Pharmaceutical products for CNS disorders are developed and commercialized. | |
| hmnc-brainhealth.com | 2010 | Munich, Germany | $24.64M | – | Targeted therapies and personalized tests for neuropsychiatric disorders are developed. | |
| evecxia.com | 2013 | Durham, United States | $14.85M | – | Therapies for CNS disorders are developed by Evecxia Therapeutics. |
Detailed competitors of Synchroneuron
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synchroneuron
Complete news archive for Synchroneuron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Synchroneuron
10 companies that operate in the same segment as Synchroneuron (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Synchroneuron
Synchroneuron was founded in 2006 and raised its 1st funding round 6 years after it was founded.
Synchroneuron is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
Barry Fogel is the current CEO of Synchroneuron. They have also founded this company.
Synchroneuron is a funded company, having raised a total of $26M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Feb 2012.
Synchroneuron was founded in 2006 and is based in Newton, United States. As a clinical-stage biopharmaceutical company, operations center on drug development for neuropsychiatric conditions including tardive dyskinesia and Tourette syndrome. The lead product, SNC-102, a sustained-release version of acamprosate calcium, is under evaluation in phase 2 trials for tardive dyskinesia and Tourette syndrome, as well as phase 1 trials for combat-related posttraumatic stress disorder.
Synchroneuron's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Synchroneuron has 1 investor. Key investors include Morningside China.